Pacira BioSciences (PCRX) Director Sale: 2,354 Shares via 10b5-1 Plan

Rhea-AI Filing Summary

Ceesay Abraham, a director of Pacira BioSciences, Inc. (PCRX), reported a sale of 2,354 shares of the issuer's common stock on 09/04/2025 at a price of $27.19 per share, executed under a previously adopted Rule 10b5-1 trading plan. After the reported disposition, the reporting person beneficially owns 9,039 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/08/2025. The filing indicates the transaction code S (sale) and explicitly states the sale was effected pursuant to the 10b5-1 plan.

Positive

• Disclosure compliance: Form 4 reports transaction date, price, share amounts, and cites Rule 10b5-1 plan
• Use of 10b5-1 plan: Sale executed pursuant to a pre-established trading plan, which documents intent and timing

Negative

• Insider disposition: Director sold 2,354 shares, reducing holdings to 9,039 shares
• No company context provided: Filing contains no information on company performance or reasons beyond the 10b5-1 statement

Insights

Corporate Governance Expert

TL;DR: Director sale executed under a pre-established 10b5-1 plan; procedural compliance appears documented.

The Form 4 shows a director-initiated sale of 2,354 shares at $27.19, with the filer retaining 9,039 shares post-transaction. The filing explicitly references a Rule 10b5-1 trading plan, which, if properly adopted and documented, provides an affirmative defense to insider trading allegations. The filing is signed by an attorney-in-fact, consistent with delegated execution. This disclosure fulfills Section 16 reporting requirements by identifying the reporting person, transaction date, price, and ownership after the sale.

Securities Analyst

TL;DR: Transaction is a routine director sale under a 10b5-1 plan; no additional financial metrics disclosed.

The record lists a single non-derivative sale and no acquisitions or derivative transactions. The sale amount and post-sale holdings are clearly stated, but the Form 4 contains no financial performance data or company-specific material updates. As provided, the transaction informs share movement by an insider but does not on its own indicate a change in company fundamentals.

09/08/2025 - 05:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ceesay Abraham

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2025		S		2,354(1)	D	$27.19	9,039	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pacira BioSciences director Ceesay Abraham report on Form 4 (PCRX)?

The director reported a sale of 2,354 shares on 09/04/2025 at $27.19 per share and holds 9,039 shares after the sale.

Was the sale by the director of PCRX covered by a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was effected pursuant to a previously adopted Rule 10b5-1 trading plan.

Who filed the Form 4 for the reporting person?

The Form 4 is signed by Kristen Williams, Attorney-in-Fact, on behalf of the reporting person, dated 09/08/2025.

How many shares does the reporting person own after the reported transaction?

The reporting person beneficially owns 9,039 shares following the reported sale.

What transaction code is used for the sale on the Form 4?

The transaction is reported with code S, indicating a sale.